Clinical Trial Update: The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating once-daily mexiletine prolonged-release for patients with myotonic dystrophy type 1 and type 2, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Mexiletine PR (Mexiletine)

Snippet

Sponsor: Lupin Ltd. | Conditions: Myotonic Dystrophy | Phase 3 | Status: RECRUITING